证券代码：688468 证券简称：科美诊断 公告编号：2023-067 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动属于股份减持，不触及要约收购。 本次权益变动后，科美诊断技术股份有限公司（以下简称"公司"）股 东横琴君联致康投资企业（有限合伙）（以下简称"横琴君联致康"）及一致行 动人LOYAL CLASS LIMITED（以下简称"LOYAL CLASS"）合计持有公司股份 从43,131,615股减少至38,640,480股，占公司总股本比例从10.76%减少至9.64%。 （距前次公司于2023年3月16日披露的《关于持股5%以上股东权益变动达到1% 的提示性公告》（公告编号：2023-015），上述股东减持比例已达到1%） 本次权益变动不会导致公司控股股东及实际控制人发生变化。 公司于2023年11月3日收到公司股东横琴君联致康及其一致行动人LOYAL CLASS出具的《关于减持科美诊断技术股份有限公司股份累计达1%的告知函》 ，现将其有关权益变动情况告知如下： 一、本次权益变动基 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥126,051,343.20, a decrease of 7.58% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2023 was ¥43,606,643.33, down 10.51% year-on-year[3]. - The net profit excluding non-recurring gains and losses was ¥41,609,611.68, an increase of 6.63% compared to the same period last year[3]. - Total revenue for the first three quarters of 2023 was CNY 345,267,780.87, a decrease of 4.6% compared to CNY 359,915,767.68 in the same period of 2022[17]. - Net profit for Q3 2023 reached CNY 120,238,363.98, an increase of 1.7% compared to CNY 118,250,804.17 in Q3 2022[19]. - Basic and diluted earnings per share for Q3 2023 were both CNY 0.30, compared to CNY 0.29 in Q3 2022[20]. - Operating profit for Q3 2023 was CNY 136,508,794.26, slightly up from CNY 133,965,186.43 in Q3 2022, indicating a growth of 1.1%[18]. - Operating profit increased significantly to CNY 35,396,236.83, up 189.5% from CNY 12,187,317.17 in the previous year[30]. - Net profit for the first three quarters of 2023 reached CNY 39,655,038.70, representing a 107.5% increase from CNY 19,117,201.98 in 2022[30]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,725,319,141.21, representing an increase of 8.43% from the end of the previous year[4]. - As of September 30, 2023, the company's total current assets amounted to ¥1,094,790,539.73, a decrease from ¥1,165,252,004.65 at the end of 2022, representing a decline of approximately 6.05%[13]. - The total assets as of September 30, 2023, were CNY 1,017,896,612.42, a decrease from CNY 1,131,638,710.08 at the end of 2022[27]. - The total current assets decreased to CNY 641,393,396.62 as of September 30, 2023, from CNY 768,574,860.71 at the end of 2022, reflecting a decline of 16.5%[26]. - Total liabilities increased to CNY 363,652,526.37 from CNY 210,591,173.95, reflecting a significant rise in financial obligations[15]. - The total liabilities as of September 30, 2023, were CNY 13,132,734.71, down from CNY 27,382,869.17 at the end of 2022[27]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥124,199,391.92, a decrease of 37.39% compared to the previous year[4]. - The net cash flow from operating activities for Q3 2023 was CNY 124,199,391.92, down 37.3% from CNY 198,363,572.85 in Q3 2022[23]. - In the first three quarters of 2023, the cash inflow from operating activities was CNY 416,659,830.96, a decrease of 3.3% compared to CNY 433,799,291.80 in the same period of 2022[22]. - The company reported a net cash outflow of CNY 64,614,801.88 in Q3 2023, contrasting with a net cash inflow of CNY 57,943,978.99 in Q3 2022[24]. - The total cash inflow from investment activities in the first three quarters of 2023 was CNY 1,830,639,554.31, a decrease of 27.4% compared to CNY 2,520,291,030.32 in the same period of 2022[23]. - The net cash flow from investment activities for Q3 2023 was -CNY 200,962,217.69, worsening from -CNY 61,664,292.63 in Q3 2022[23]. Research and Development - The company's R&D expenditure for Q3 2023 was ¥21,440,724.46, a decrease of 10.25% year-on-year, accounting for 17.01% of operating revenue[4]. - The company reported a decrease in research and development expenses to CNY 47,237,479.89 from CNY 51,337,884.31 in the previous year, a reduction of 7.3%[18]. - Research and development expenses decreased to CNY 27,827,230.08, down 15.9% from CNY 33,055,264.49 in the same period last year[29]. - The company added 8 new domestic medical device certificates during the reporting period, including 6 Class II and 2 Class III registrations[12]. - The company obtained 23 new patents during the reporting period, including 11 domestic invention patents and 6 utility model patents[12]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[16]. - The company plans to continue focusing on market expansion and new product development to drive future growth[34].

证券代码：688468 证券简称：科美诊断 公告编号：2023-066 （一）审议通过《公司2023年第三季度报告》 监事会认为：公司2023年第三季度报告的编制和审议程序符合相关法律法 规及《公司章程》等内部规章制度的规定，其内容能够真实、准确、完整地反 映公司报告期内的财务状况和经营成果等事项，不存在任何虚假记载、误导性 陈述或者重大遗漏。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 科美诊断技术股份有限公司（以下简称"公司"）第二届监事会第五次会议 于2023年10月30日以现场结合通讯方式召开，本次会议通知于2023年10月23日 以邮件方式送达公司全体监事。本次会议由监事会主席练子富先生主持，应参 与表决监事3人，实际参与表决监事3人。本次会议的召集、召开程序符合《中 华人民共和国公司法》等法律、法规、规章、规范性文件和《科美诊断技术股 份有限公司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法、 有效。 二、监事会会议审议情况 经与会监事表决，审议通过以下议案： 表决结果： ...

重要内容提示： 大股东持股的基本情况 证券代码：688468 证券简称：科美诊断 公告编号：2023-065 本次减持计划实施前，科美诊断技术股份有限公司（以下简称"公司"）股东 横琴君联致康投资企业（有限合伙）（以下简称"横琴君联致康"）及其一致行动 人 LOYAL CLASS LIMITED（以下简称"LOYAL CLASS"，）分别持有公司股份 24,620,486 股、16,869,994 股（合计持有 41,490,480 股），分别占公司总股本的 6.14%、4.21%（合计占公司总股本的 10.35%）。 科美诊断技术股份有限公司关于持股 5%以上股东 减持计划时间过半未减持股份的进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 上述股份来源均为公司首次公开发行股票并上市前持有的股份，且已于 2022 年 4 月 11 日解除限售并上市流通。 | | 股东名称 | 持股数量 | 持股比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | --- | | | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科美诊断技术股份有限公司（以下简称"公司"或"科美诊断"）于近日 收到了 1 项国家知识产权局颁发的发明专利证书，现将具体情况公告如下： 证券代码：688468 证券简称：科美诊断 公告编号：2023-064 上述发明专利权的取得不会对公司目前的经营状况产生重大的影响，但有 利于进一步完善公司的知识产权体系，充分发挥公司的知识产权优势，促进公 司技术创新及产品结构的不断丰富，从而提升公司的核心竞争力。 特此公告。 科美诊断技术股份有限公司董事会 2023年 9 月 19日 1 一、发明证书的基本情况 | 发明专利名称 | 专利号 | 专利申请日 | 授权公告日 | 专利权人 | 专利期限 | | --- | --- | --- | --- | --- | --- | | 光检测测量系统 | ZL202310587214.2 | 2023 年 5 月 24 日 | 2023 年 9 月 15 日 | 科美诊断 | 二十年 | 二、对公司的影响 上述专利保护技术为公司自主研发,为 ...

中信证券股份有限公司 关于科美诊断技术股份有限公司 2023 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为科 美诊断技术股份有限公司（以下简称"科美诊断"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、 《上海证券交易所科创板股票上市规则》、《科创板上市公司持续监管办法 （试行）》等规定，负责科美诊断上市后的持续督导工作，并出具本持续督导 半年度跟踪报告。 | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 保荐机构已建立健全并有效执行了持续 | | 1 | 度，并针对具体的持续督导工作制定相 | | | | | 督导制度，并制定了相应的工作计划。 | | | 应的工作计划。 | | | | 根据中国证监会相关规定，在持续督导 | 保荐机构已与科美诊断签订承销及保荐 | | | 工作开始前，与上市公司签署持续督导 | 协议，该协议明确了双方在持续督导期 | | 2 | 协议，明确双方在持续督导期间的权利 | 间的权利和义务，并报上海证券交易所 | ...

科美诊断技术股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688468 证券简称：科美诊断 公告编号：2023-063 重要内容提示： 会议召开时间：2023年9月21日（星期四）下午 13:00-14:00 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2023年9月14日（星期四）至9月20日（星期三）16:00前登录上 证路演中心网站首页点击"提问预征集"栏目或通过科美诊断技术股份有限公司 （以下简称"公司"）邮箱ir@chemclin.com进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 公司于 2023 年 8 月 30 日在上海证券交易所网站（www.sse.com.cn）发布了 《2023 年半年度报告》，为便于广大投资者更全面深入地了解公司 2023 年半年 度经营成果、财务状况，公司计划于 2023 年 9 月 ...

科美诊断技术股份有限公司（以下简称"公司"）近日获得北京市药品监 督管理局颁发的1项《医疗器械注册证》，现将具体情况公告如下： | 注册人 | 产品名称 | 注册 | 注册证编号 | 注册证 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 名称 | | 类别 | | 有效期 | | | 科美诊断 技术股份 | 免疫球蛋白E（IgE） 测定试剂盒（光激化 | Ⅱ | 京械注准 | 2023/8/22- | 本试剂盒用于体外定量测定人血清 | | | | | 20232400518 | 2028/8/21 | 中免疫球蛋白E（IgE）的含量。 | | 有限公司 | 学发光法） | | | | | 证券代码：688468 证券简称：科美诊断 公告编号：2023-062 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鉴于上述产品需要在北京市药品监督管理局企业服务平台进行信息登记后 方可上市销售，产品上市后的实际销售情况取决于未来市场的推广效果，目前 尚无法预测上述产品对公司未来业 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2023, representing a year-on-year increase of 20%[1]. - The company's operating revenue for the first half of 2023 was CNY 219.22 million, a decrease of 1.93% compared to CNY 223.53 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was CNY 76.63 million, an increase of 10.23% from CNY 69.52 million year-on-year[21]. - Basic earnings per share for the first half of 2023 were CNY 0.19, up 11.76% from CNY 0.17 in the same period last year[22]. - The gross profit margin improved to 60%, up from 55% in the same period last year, reflecting better cost management[1]. - The net cash flow from operating activities decreased by 41.75% to CNY 67.71 million, primarily due to increased tax payments, procurement costs, and promotional expenses[23]. - The company's total assets at the end of the reporting period were CNY 1.61 billion, reflecting a 1.23% increase from CNY 1.59 billion at the end of the previous year[21]. - The net assets attributable to shareholders decreased by 4.53% to CNY 1.32 billion from CNY 1.38 billion at the end of the previous year[21]. Market Expansion and Strategy - The company expects a revenue growth forecast of 25% for the second half of 2023, driven by new product launches and market expansion strategies[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[1]. - A strategic acquisition of a local biotech firm is in progress, expected to enhance the company's product portfolio and market reach[1]. - The company continues to focus on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[26]. Research and Development - Research and development expenses increased by 30% to RMB 15 million, focusing on the development of new diagnostic technologies[1]. - The company's R&D expenditure accounted for 18.71% of operating revenue, an increase of 2.34 percentage points compared to 16.37% in the previous year[22]. - The total R&D investment amounted to ¥41,023,340.46, a 12.10% increase compared to the previous year, with the proportion of R&D investment to operating income rising by 2.34 percentage points to 18.71%[61]. - The company is focusing on the development of its intelligent cloud platform V2.0 and the LiCA® AT 5000 fully automated chemical luminescence immunoassay system, leading to increased R&D investment[62]. - The company has developed a new phage display platform to improve antibody raw material discovery efficiency, contributing to cost reduction and efficiency enhancement[66]. Product Development and Innovation - The company has launched a new product line, LiCA® series, which has shown promising initial sales, contributing to 5% of total revenue[1]. - The company has developed 77 products in the LiCA® series, covering common clinical detection projects, with performance metrics meeting or exceeding international brands[48]. - The LiCA® Smart device received its medical device registration certificate on May 26, 2020, while the LiCA® AT5000 is currently under development[30]. - The company has established a proprietary light-initiated chemiluminescence technology platform, resulting in the development of the LiCA® product series, which demonstrates superior sensitivity and specificity compared to leading international brands[71]. - The company is advancing the development of the LiCA®5000, a high-speed immunofluorescence line instrument, to enhance its product offerings[89]. Regulatory and Risk Factors - The company has identified potential risks related to regulatory changes and market competition, which are detailed in the risk factors section of the report[1]. - The company faces risks related to new product development and registration, which typically takes 3-5 years and involves multiple stages[95]. - There is a risk of intellectual property leakage or infringement, which could adversely affect the company's operations[96]. - The company is at risk of losing core technical personnel, which could delay ongoing projects and impact future R&D capabilities[97]. - The rapid technological advancements in the in vitro diagnostic industry pose a risk if the company fails to keep up with new technologies and products[99]. Environmental Responsibility - The company has established comprehensive environmental protection regulations and trained employees on pollutant classification and disposal[133]. - Waste gas generated during experiments is collected and treated through activated carbon filtration, meeting national emission standards[134]. - The company has adopted clean energy and renewable energy technologies to reduce carbon emissions and improve energy efficiency[136]. - The company has committed to environmental responsibilities and has not faced any administrative penalties related to environmental issues[133]. Shareholder Commitments and Governance - The company commits to a 36-month lock-up period for shares held prior to the IPO, prohibiting any transfer or management delegation of these shares[146]. - The company will adhere to the rules set by the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding shareholding and reduction[152]. - The company has made commitments regarding profit distribution policies and shareholder return plans post-listing[143]. - The company guarantees not to use its position as a controlling shareholder to harm the legitimate rights and interests of Kemei Diagnostics and its shareholders, especially minority shareholders[175]. Legal Matters - The company has ongoing significant litigation regarding the infringement of trade secrets, with a claim for economic damages of 68 million yuan and additional reasonable expenses of 1 million yuan[180]. - The company is involved in multiple lawsuits, including a commercial defamation case and a trademark infringement case, with various outcomes pending[183]. - The company has been proactive in publishing statements to mitigate the impact of ongoing litigation on its reputation[182].

科美诊断技术股份有限公司独立董事 关于第二届董事会第四次会议相关议案的独立意见 科美诊断技术股份有限公司（以下简称"公司"）第二届董事会第四次会议于 2023 年 8 月 28 日以现场会议结合通讯表决的方式召开。根据《上海证券交易所 科创板股票上市规则》、《上市公司独立董事规则》、《上市公司治理准则》及《公 司章程》等相关规章制度的规定，本着谨慎的原则，基于独立判断的立场，现对 公司第二届董事会第四次会议审议的有关事项发表如下独立意见： 一、《关于公司 2023 年半年度募集资金存放与使用情况的专项报告的议案》 的独立意见 我们认为：公司《2023 年半年度募集资金存放与使用情况的专项报告》内 容真实、准确、完整，不存在虚假记载、误导性陈述和重大遗漏。公司 2023 年 半年度募集资金存放与实际使用情况符合《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》、《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》等的有关规定，公司对募集资金进行了专户存储和 专项使用，不存在变相改变募集资金用途的情形，不存在违规存放与使用募集资 金的情形，不存在损害公司及中小股东合法权益的情 ...